Background: The neuropathological hallmark of Huntington's disease (HD) is progressive striatal loss starting several years prior to clinical onset. In the past decade, whole-brain magnetic resonance imaging (MRI) studies have provided accumulating evidence for widely distributed cortical and subcortical atrophy in the early course of the disease. Objective: In order to synthesize current morphometric MRI findings and to investigate the impact of clinical and genetic features on structural changes, we performed a coordinate-based meta-analysis of voxel-based morphometry (VBM) studies in HD. Methods: Twenty HD samples derived from 17 studies were integrated in the analysis comparing a total of 685 HD mutation carriers [345 presymptomatic (pre-HD) and 340 symptomatic (symp-HD) subjects] and 507 controls. Convergent findings across studies were delineated using the anatomical likelihood estimation approach. Effects of genetic and clinical parameters on the likelihood of observing VBM findings were calculated by means of correlation analyses. Results: Pre-HD studies featured convergent evidence for neurodegeneration in the basal ganglia, amygdala, thalamus, insula and occipital regions. In symp-HD, cerebral atrophy was more pronounced and spread to cortical regions (i.e. inferior frontal, premotor, sensorimotor, midcingulate, frontoparietal and temporoparietal cortices). Higher cytosine-adenosine-guanosine repeats were associated with striatal degeneration, while parameters of disease progression and motor impairment additionally correlated with cortical atrophy, especially in sensorimotor areas. Conclusion: This first quantitative meta-analysis in HD demonstrates the extent of striatal atrophy and further consistent extrastriatal degeneration before clinical conversion. Sensorimotor areas seem to be core regions affected in symp-HD and, along with widespread cortical atrophy, may account for the clinical heterogeneity in HD.

1.
The Huntington's Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993;72:971-983.
2.
Aylward EH, Sparks BF, Field KM, Yallapragada V, Shpritz BD, Rosenblatt A, Brandt J, Gourley LM, Liang K, Zhou H, Margolis RL, Ross CA: Onset and rate of striatal atrophy in preclinical Huntington disease. Neurology 2004;63:66-72.
3.
Paulsen JS, Nopoulos PC, Aylward E, Ross CA, Johnson H, Magnotta VA, Juhl A, Pierson RK, Mills J, Langbehn D, Nance M; PREDICT-HD Investigators and Coordinators of the Huntington's Study Group (HSG): Striatal and white matter predictors of estimated diagnosis for Huntington disease. Brain Res Bull 2010;82:201-207.
4.
Bohanna I, Georgiou-Karistianis N, Hannan AJ, Egan GF: Magnetic resonance imaging as an approach towards identifying neuropathological biomarkers for Huntington's disease. Brain Res Rev 2008;58:209-225.
5.
Paulsen JS, Hayden M, Stout JC, Langbehn DR, Aylward E, Ross CA, Guttman M, Nance M, Kieburtz K, Oakes D, Shoulson I, Kayson E, Johnson S, Penziner E: Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol 2006;63:883-890.
6.
Tabrizi SJ, Langbehn DR, Leavitt BR, Roos RA, Durr A, Craufurd D, Kennard C, Hicks SL, Fox NC, Scahill RI, Borowsky B, Tobin AJ, Rosas HD, Johnson H, Reilmann R, Landwehrmeyer B, Stout JC: Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 2009;8:791-801.
7.
Harris GJ, Codori AM, Lewis RF, Schmidt E, Bedi A, Brandt J: Reduced basal ganglia blood flow and volume in pre-symptomatic, gene-tested persons at-risk for Huntington's disease. Brain 1999;122:1667-1678.
8.
Paulsen JS, Magnotta VA, Mikos AE, Paulson HL, Penziner E, Andreasen NC, Nopoulos PC: Brain structure in preclinical Huntington's disease. Biol Psychiatry 2006;59:57-63.
9.
van den Bogaard SJ, Dumas EM, Acharya TP, Johnson H, Langbehn DR, Scahill RI, Tabrizi SJ, van Buchem MA, van der Grond J, Roos RA: Early atrophy of pallidum and accumbens nucleus in Huntington's disease. J Neurol 2011;258:412-420.
10.
Rosas HD, Hevelone ND, Zaleta AK, Greve DN, Salat DH, Fischl B: Regional cortical thinning in preclinical Huntington disease and its relationship to cognition. Neurology 2005;65:745-747.
11.
Nopoulos PC, Aylward EH, Ross CA, Johnson HJ, Magnotta VA, Juhl AR, Pierson RK, Mills J, Langbehn DR, Paulsen JS; PREDICT-HD Investigators Coordinators of Huntington Study Group (HSG): Cerebral cortex structure in prodromal Huntington disease. Neurobiol Dis 2010;40:544-554.
12.
Ashburner J, Friston KJ: Voxel-based morphometry - the methods. Neuroimage 2000;11:805-821.
13.
Douaud G, Gaura V, Ribeiro MJ, Lethimonnier F, Maroy R, Verny C, Krystkowiak P, Damier P, Bachoud-Levi AC, Hantraye P, Remy P: Distribution of grey matter atrophy in Huntington's disease patients: a combined ROI-based and voxel-based morphometric study. Neuroimage 2006;32:1562-1575.
14.
Klöppel S, Chu C, Tan GC, Draganski B, Johnson H, Paulsen JS, Kienzle W, Tabrizi SJ, Ashburner J, Frackowiak RS: Automatic detection of preclinical neurodegeneration: presymptomatic Huntington disease. Neurology 2009;72:426-431.
15.
Klöppel S, Stonnington CM, Petrovic P, Mobbs D, Tuscher O, Craufurd D, Tabrizi SJ, Frackowiak RS: Irritability in pre-clinical Huntington's disease. Neuropsychologia 2010;48:549-557.
16.
Stoffers D, Sheldon S, Kuperman JM, Goldstein J, Corey-Bloom J, Aron AR: Contrasting gray and white matter changes in preclinical Huntington disease: an MRI study. Neurology 2010;74:1208-1216.
17.
Wolf RC, Vasic N, Schonfeldt-Lecuona C, Landwehrmeyer GB, Ecker D: Dorsolateral prefrontal cortex dysfunction in presymptomatic Huntington's disease: evidence from event-related fMRI. Brain 2007;130:2845-2857.
18.
Gavazzi C, Nave RD, Petralli R, Rocca MA, Guerrini L, Tessa C, Diciotti S, Filippi M, Piacentini S, Mascalchi M: Combining functional and structural brain magnetic resonance imaging in Huntington disease. J Comput Assist Tomogr 2007;31:574-580.
19.
Gomez-Anson B, Alegret M, Munoz E, Monte GC, Alayrach E, Sanchez A, Boada M, Tolosa E: Prefrontal cortex volume reduction on MRI in preclinical Huntington's disease relates to visuomotor performance and CAG number. Parkinsonism Relat Disord 2009;15:213-219.
20.
Henley SM, Wild EJ, Hobbs NZ, Scahill RI, Ridgway GR, Macmanus DG, Barker RA, Fox NC, Tabrizi SJ: Relationship between CAG repeat length and brain volume in premanifest and early Huntington's disease. J Neurol 2009;256:203-212.
21.
Ille R, Schafer A, Scharmuller W, Enzinger C, Schoggl H, Kapfhammer HP, Schienle A: Emotion recognition and experience in Huntington disease: a voxel-based morphometry study. J Psychiatry Neurosci 2011;36:383-390.
22.
Kassubek J, Juengling FD, Kioschies T, Henkel K, Karitzky J, Kramer B, Ecker D, Andrich J, Saft C, Kraus P, Aschoff AJ, Ludolph AC, Landwehrmeyer GB: Topography of cerebral atrophy in early Huntington's disease: a voxel based morphometric MRI study. J Neurol Neurosurg Psychiatry 2004;75:213-220.
23.
Mühlau M, Weindl A, Wohlschlager AM, Gaser C, Stadtler M, Valet M, Zimmer C, Kassubek J, Peinemann A: Voxel-based morphometry indicates relative preservation of the limbic prefrontal cortex in early Huntington disease. J Neural Transm 2007;114:367-372.
24.
Nave RD, Ginestroni A, Tessa C, Giannelli M, Piacentini S, Filippi M, Mascalchi M: Regional distribution and clinical correlates of white matter structural damage in Huntington disease: a tract-based spatial statistics study. AJNR Am J Neuroradiol 2010;31:1675-1681.
25.
Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J: Executive dysfunction in early stages of Huntington's disease is associated with striatal and insular atrophy: a neuropsychological and voxel-based morphometric study. J Neurol Sci 2005;239:11-19.
26.
Thieben MJ, Duggins AJ, Good CD, Gomes L, Mahant N, Richards F, McCusker E, Frackowiak RS: The distribution of structural neuropathology in pre-clinical Huntington's disease. Brain 2002;125:1815-1828.
27.
Wolf RC, Vasic N, Schonfeldt-Lecuona C, Ecker D, Landwehrmeyer GB: Cortical dysfunction in patients with Huntington's disease during working memory performance. Hum Brain Mapp 2009;30:327-339.
28.
Zimbelman JL, Paulsen JS, Mikos A, Reynolds NC, Hoffmann RG, Rao SM: fMRI detection of early neural dysfunction in preclinical Huntington's disease. J Int Neuropsychol Soc 2007;13:758-769.
29.
Shoulson I, Fahn S: Huntington disease: clinical care and evaluation. Neurology 1979;29:1-3.
30.
Eickhoff SB, Laird AR, Grefkes C, Wang LE, Zilles K, Fox PT: Coordinate-based activation likelihood estimation meta-analysis of neuroimaging data: a random-effects approach based on empirical estimates of spatial uncertainty. Hum Brain Mapp 2009;30:2907-2926.
31.
Turkeltaub PE, Eden GF, Jones KM, Zeffiro TA: Meta-analysis of the functional neuroanatomy of single-word reading: method and validation. Neuroimage 2002;16:765-780.
32.
Turkeltaub PE, Eickhoff SB, Laird AR, Fox M, Wiener M, Fox P: Minimizing within-experiment and within-group effects in activation likelihood estimation meta-analyses. Hum Brain Mapp 2012;33:1-13.
33.
Schroeter ML, Raczka K, Neumann J, Yves von Cramon D: Towards a nosology for frontotemporal lobar degenerations - a meta-analysis involving 267 subjects. Neuroimage 2007;36:497-510.
34.
Schroeter ML, Raczka K, Neumann J, von Cramon DY: Neural networks in frontotemporal dementia - a meta-analysis. Neurobiol Aging 2008;29:418-426.
35.
Glahn DC, Laird AR, Ellison-Wright I, Thelen SM, Robinson JL, Lancaster JL, Bullmore E, Fox PT: Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis. Biol Psychiatry 2008;64:774-781.
36.
Nichols T, Brett M, Andersson J, Wager T, Poline JB: Valid conjunction inference with the minimum statistic. Neuroimage 2005;25:653-660.
37.
Caspers S, Zilles K, Laird AR, Eickhoff SB: ALE meta-analysis of action observation and imitation in the human brain. Neuroimage 2010;50:1148-1167.
38.
Eickhoff SB, Stephan KE, Mohlberg H, Grefkes C, Fink GR, Amunts K, Zilles K: A new SPM toolbox for combining probabilistic cytoarchitectonic maps and functional imaging data. Neuroimage 2005;25:1325-1335.
39.
Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH: CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol 1997;41:689-692.
40.
Langbehn DR, Brinkman RR, Falush D, Paulsen JS, Hayden MR: A new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length. Clin Genet 2004;65:267-277.
41.
Behrens TE, Johansen-Berg H, Woolrich MW, Smith SM, Wheeler-Kingshott CA, Boulby PA, Barker GJ, Sillery EL, Sheehan K, Ciccarelli O, Thompson AJ, Brady JM, Matthews PM: Non-invasive mapping of connections between human thalamus and cortex using diffusion imaging. Nat Neurosci 2003;6:750-757.
42.
Kassubek J, Juengling FD, Ecker D, Landwehrmeyer GB: Thalamic atrophy in Huntington's disease co-varies with cognitive performance: a morphometric MRI analysis. Cereb Cortex 2005;15:846-853.
43.
Rosas HD, Salat DH, Lee SY, Zaleta AK, Pappu V, Fischl B, Greve D, Hevelone N, Hersch SM: Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain 2008;131:1057-1068.
44.
Bohanna I, Georgiou-Karistianis N, Egan GF: Connectivity-based segmentation of the striatum in Huntington's disease: vulnerability of motor pathways. Neurobiol Dis 2011;42:475-481.
45.
Eickhoff SB, Jbabdi S, Caspers S, Laird AR, Fox PT, Zilles K, Behrens TE: Anatomical and functional connectivity of cytoarchitectonic areas within the human parietal operculum. J Neurosci 2010;30:6409-6421.
46.
Alexander GE, DeLong MR, Strick PL: Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Annu Rev Neurosci 1986;9:357-381.
47.
Hobbs NZ, Pedrick AV, Say MJ, Frost C, Dar Santos R, Coleman A, Sturrock A, Craufurd D, Stout JC, Leavitt BR, Barnes J, Tabrizi SJ, Scahill RI: The structural involvement of the cingulate cortex in premanifest and early Huntington's disease. Mov Disord 2011;26:1684-1690.
48.
Thu DC, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RL: Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington's disease. Brain 2010;133:1094-1110.
49.
Eickhoff SB, Heim S, Zilles K, Amunts K: A systems perspective on the effective connectivity of overt speech production. Philos Transact A Math Phys Eng Sci 2009;367:2399-2421.
50.
Culham JC, Cavina-Pratesi C, Singhal A: The role of parietal cortex in visuomotor control: what have we learned from neuroimaging? Neuropsychologia 2006;44:2668-2684.
51.
Rupp J, Dzemidzic M, Blekher T, West J, Hui S, Wojcieszek J, Saykin AJ, Kareken DA, Foroud T: Comparison of vertical and horizontal saccade measures and their relation to gray matter changes in premanifest and manifest Huntington disease. J Neurol 2012;259:267-276.
52.
Kipps CM, Duggins AJ, McCusker EA, Calder AJ: Disgust and happiness recognition correlate with anteroventral insula and amygdala volume respectively in preclinical Huntington's disease. J Cogn Neurosci 2007;19:1206-1217.
53.
Rosas HD, Reuter M, Doros G, Lee SY, Triggs T, Malarick K, Fischl B, Salat DH, Hersch SM: A tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study. Mov Disord 2011;26:1691-1697.
54.
Mühlau M, Gaser C, Wohlschlager AM, Weindl A, Stadtler M, Valet M, Zimmer C, Kassubek J, Peinemann A: Striatal gray matter loss in Huntington's disease is leftward biased. Mov Disord 2007;22:1169-1173.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.